TY - JOUR
T1 - Factors facilitating and hindering development of a medication use review service in Eastern Europe and Iran - cross-sectional exploratory study
AU - Tuula, Anita
AU - Volmer, Daisy
AU - Jõhvik, Liisa
AU - Rutkovska, Ieva
AU - Trečiokienė, Indre
AU - Merks, Piotr
AU - Waszyk-Nowaczyk, Magdalena
AU - Drozd, Mariola
AU - Tatarević, Alena
AU - Radovanlija, Maja
AU - Pacadi, Carmen
AU - Meštrović, Arijana
AU - Viola, Réka
AU - Soós, Gyöngyvér
AU - Rais, Cristina
AU - Táerel, Adriana Elena
AU - Kuzelova, Magdalena
AU - Zare, Marziyeh
AU - Peymani, Payam
AU - Oona, Marje
AU - Scott, Michael
N1 - Funding Information:
European Association of Faculties of Pharmacy PRD 2019 grant for the project ?Develop-ment and Implementation of Medication Use Review Services at Community Pharmacy in Eastern European countries?.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/9
Y1 - 2021/9
N2 - Polypharmacy is a common issue in patients with chronic diseases. Eastern-European countries and Iran are exploring possibilities for implementing the Medication Use Review (MUR) as a measure for optimizing medication use and ensuring medication safety in polypharmacy patients. The aim of this study was to gain insights into the development of the community pharmacy sector and map facilitators and barriers of MUR in Eastern Europe and Iran. The representatives of the framework countries received a questionnaire on community pharmacy sector indicators, current and future developments of pharmacies, and factors encouraging and hindering MUR. To answer the questionnaire, all representatives performed document analysis, literature review, and qualitative interviews with key stakeholders. The socio-ecological model was used for inductive thematic analysis of the identified factors. Current community pharmacist competencies in framework countries were more related to traditional pharmacy services. Main facilitators of MUR were increase in polypharmacy and pharmaceutical waste, and access to patients’ electronic list of medications by pharmacists. Main barriers included the service being unfamiliar, lack of funding and private consultation areas. Pharmacists in the framework countries are well-placed to provide MUR, however, the service needs more introduction and barriers mostly on organizational and public policy levels must be addressed.
AB - Polypharmacy is a common issue in patients with chronic diseases. Eastern-European countries and Iran are exploring possibilities for implementing the Medication Use Review (MUR) as a measure for optimizing medication use and ensuring medication safety in polypharmacy patients. The aim of this study was to gain insights into the development of the community pharmacy sector and map facilitators and barriers of MUR in Eastern Europe and Iran. The representatives of the framework countries received a questionnaire on community pharmacy sector indicators, current and future developments of pharmacies, and factors encouraging and hindering MUR. To answer the questionnaire, all representatives performed document analysis, literature review, and qualitative interviews with key stakeholders. The socio-ecological model was used for inductive thematic analysis of the identified factors. Current community pharmacist competencies in framework countries were more related to traditional pharmacy services. Main facilitators of MUR were increase in polypharmacy and pharmaceutical waste, and access to patients’ electronic list of medications by pharmacists. Main barriers included the service being unfamiliar, lack of funding and private consultation areas. Pharmacists in the framework countries are well-placed to provide MUR, however, the service needs more introduction and barriers mostly on organizational and public policy levels must be addressed.
KW - Barriers
KW - Community pharmacy
KW - Medication review
KW - MUR
KW - Pharmacist
UR - http://www.scopus.com/inward/record.url?scp=85114931225&partnerID=8YFLogxK
U2 - 10.3390/healthcare9091207
DO - 10.3390/healthcare9091207
M3 - Article
AN - SCOPUS:85114931225
SN - 2227-9032
VL - 9
JO - Healthcare (Switzerland)
JF - Healthcare (Switzerland)
IS - 9
M1 - 1207
ER -